Cargando…

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial

AIM: To evaluate the efficacy and safety of dulaglutide 3.0 and 4.5 mg versus 1.5 mg when used as an add‐on to metformin in subgroups defined by age (<65 and ≥65 years). MATERIALS AND METHODS: Of 1842 patients included in this post hoc analysis, 438 were aged 65 years or older and 1404 were young...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frias, Juan P., Bonora, Enzo, Nevárez Ruiz, Luis, Hsia, Stanley H., Jung, Heike, Raha, Sohini, Cox, David A., Bethel, M. Angelyn, Konig, Manige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518960/ https://www.ncbi.nlm.nih.gov/pubmed/34159708 http://dx.doi.org/10.1111/dom.14469

Ejemplares similares

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
por: Frias, Juan P., et al.
Publicado: (2021)

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
por: Bonora, Enzo, et al.
Publicado: (2021)

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study
por: Cox, David A., et al.
Publicado: (2022)

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
por: Riddle, Matthew C, et al.
Publicado: (2021)

HbA(1c) Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
por: Kwan, Anita Y.M., et al.
Publicado: (2022)

Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
por: Patel, Hiren, et al.
Publicado: (2019)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years
por: Boustani, M. A., et al.
Publicado: (2016)

OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)
por: Frias, Juan Pablo, et al.
Publicado: (2020)

A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide
por: Tham, Lai San, et al.
Publicado: (2021)

Proposal for the award of a contract for the repair work on the endwalls of the UX45 and UX65 caverns
Publicado: (2001)

Begin risk assessment for falls in women at 45, not 65
por: Harmon, Katherine J, et al.
Publicado: (2019)

Factors associated with the acceptance of employing nursing assistants aged 65 and older among those younger than 65 years old
por: Kudo, Yasushi, et al.
Publicado: (2023)

Cardiovascular diseases in patients 65 years and younger with non-cardiogenic stroke
por: Lasek-Bal, Anetta, et al.
Publicado: (2016)

General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2023)

Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review
por: Robinson, Susan, et al.
Publicado: (2020)

Triglyceride-glucose index predicts death in patients with stroke younger than 65
por: Liu, Ruishan, et al.
Publicado: (2023)

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
por: Konig, Manige, et al.
Publicado: (2020)

Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
por: Kuang, Jian, et al.
Publicado: (2020)

Reverse Total Shoulder Arthroplasty for Younger Patients: A Comparable Analysis of Patients Older and Younger Than 65 Years
por: Deliso, Marisa, et al.
Publicado: (2023)

A Depiction of Rehabilitation Patients 65 Years and Younger With Dysvascular Lower Extremity Amputation
por: Mayo, A.L., et al.
Publicado: (2019)

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data
por: Mody, Reema, et al.
Publicado: (2020)

$\beta^{-}$ decay of $^{65}$Mn to $^{65}$Fe
por: Olaizola, B., et al.
Publicado: (2013)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

Cohort Profile: The Lausanne cohort 65+ (Lc65+)
por: Henchoz, Yves, et al.
Publicado: (2021)

Prevention of diabetic eye disease: the commonest cause of blindness in individuals younger than 65 years
por: Tatti, Patrizio, et al.
Publicado: (2010)

Hypermethylation of MDFI promoter with NSCLC is specific for females, non-smokers and people younger than 65
por: Ma, Hongying, et al.
Publicado: (2018)

Reverse shoulder arthroplasty in patients aged 65 years or younger: a systematic review of the literature
por: Chelli, Mikaël, et al.
Publicado: (2019)

Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
por: Li, Qifu, et al.
Publicado: (2021)

Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
por: MacIsaac, Richard J.
Publicado: (2020)

Morbidity and Mortality After Rib Fracture in Elderly Patients (>65 Years Old) Compared to a Younger Cohort (≤65 Years of Age) at Doctor Hospital Renaissance Health
por: Mvoula, Lord, et al.
Publicado: (2022)

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age
por: Tesser, John, et al.
Publicado: (2019)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

At SC65
por: CERN PhotoLab
Publicado: (1979)

Clinical Outcomes After Cardiac Stress Testing Among US Patients Younger Than 65 Years
por: Kini, Vinay, et al.
Publicado: (2018)

Associations between the dietary inflammatory index and urinary incontinence among women younger than 65 years
por: Zhang, Shiyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ishk0d4s6l3piq5bo92jj68k7r